Pfizer acquires BioRexis in move to boost diabetes, protein drug pipeline

Share this article:
Pfizer said today it has acquired BioRexis Pharmaceutical Corporation, a privately-held biopharmaceutical firm working on several diabetes treatments and a novel technology platform for new protein drug candidates. Financial terms of the deal were not disclosed. The technology being used to develop the experimental treatments relies on protein engineering and may have the potential to improve drug tolerability, reduce dosing frequency and improve patient compliance, Pfizer said.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions